WO2006045587A1 - A process for the preparation of [1,4,5]-oxadiazepine derivatives - Google Patents

A process for the preparation of [1,4,5]-oxadiazepine derivatives Download PDF

Info

Publication number
WO2006045587A1
WO2006045587A1 PCT/EP2005/011432 EP2005011432W WO2006045587A1 WO 2006045587 A1 WO2006045587 A1 WO 2006045587A1 EP 2005011432 W EP2005011432 W EP 2005011432W WO 2006045587 A1 WO2006045587 A1 WO 2006045587A1
Authority
WO
WIPO (PCT)
Prior art keywords
oxadiazepine
preparation
reaction
water
reaction mixture
Prior art date
Application number
PCT/EP2005/011432
Other languages
French (fr)
Inventor
Dominik Faber
Beat Jau
Original Assignee
Syngenta Participations Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN2005800347444A priority Critical patent/CN101039926B/en
Priority to BRPI0517390A priority patent/BRPI0517390B8/en
Priority to US11/577,805 priority patent/US20090124800A1/en
Priority to JP2007538323A priority patent/JP5117858B2/en
Priority to EP05795620A priority patent/EP1838683B1/en
Priority to CA2579742A priority patent/CA2579742C/en
Priority to AU2005298824A priority patent/AU2005298824C1/en
Priority to DE602005014280T priority patent/DE602005014280D1/en
Application filed by Syngenta Participations Ag filed Critical Syngenta Participations Ag
Priority to KR1020077009539A priority patent/KR101317353B1/en
Priority to AT05795620T priority patent/ATE430140T1/en
Priority to EA200700766A priority patent/EA011555B1/en
Priority to MX2007004591A priority patent/MX2007004591A/en
Priority to DK05795620T priority patent/DK1838683T3/en
Publication of WO2006045587A1 publication Critical patent/WO2006045587A1/en
Priority to IL181766A priority patent/IL181766A/en
Priority to HK07113831.9A priority patent/HK1108580A1/en
Priority to US13/100,601 priority patent/US20110207925A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D273/00Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C07D273/06Seven-membered rings

Definitions

  • the present invention relates to a novel process for the preparation of [1 ,4,5]- oxadiazepines and to their use as intermediates in the preparation of herbicides of the tetrahydropyrazolodione type.
  • [1 ,4,5]-oxadiazepines can be prepared by reacting various N,N'-diacylated hydrazines with, for example, 2,2'-dichlorodiethyl ether in a polar solvent to form 4,5-diacyl-[1 ,4,5]-oxadiazepines and then removing the two acyl groups using a hydrohalic acid.
  • the present invention accordingly relates to a novel process for the preparation of [1 ,4,5]- oxadiazepine derivatives by reaction of a 4,5-diacyl-[1 ,4,5]-oxadiazepine with a base in a polar solvent and at elevated temperature.
  • Preferred 4,5-diacyl-[1 ,4,5]-oxadiazepines correspond to formula I
  • R 1 and R 2 are each independently of the other hydrogen, CrC 5 alkyl, C 1 - C 5 haloalkyl, C 2 -C 5 alkenyl, C 2 -C 5 alkynyl, phenyl, alkylphenyl, halophenyl, alkoxyphenyl, benzyl, alkylbenzyl, halobenzyl, alkoxybenzyl, d-Csalkoxy-CrCsalkyl or C 3 -C 6 cycloalkyl, or R 1 and R 2 together are CrC 4 alkylene, 1 ,2-phenylene or 1 ,8-naphthylene, and R 3 and R 4 are each independently of the other hydrogen, d-Csalkyl, Ci -C S aIkOXy-C 1 -C 5 alkyl, phenyl, alkylphenyl, halophenyl, alkoxyphenyl or benzyl.
  • R 1 and R 2 are each independently of the other hydrogen or Ci-C 5 alkyl, especially methyl.
  • R 3 and R 4 are preferably hydrogen.
  • the 4,5-diacyl-[1 ,4,5]-oxadiazepines of formula I used according the invention as starting materials are known and can be prepared in a manner known per se, for example in the manner described in WO 03/051853.
  • the yield of such starting materials can be improved in the case of the reaction of N,N'-diacylated hydrazines with, for example, 2,2'- dichlorodiethyl ether, by using hydroxides of alkali metals and alkaline earth metals as the base and by carrying out the reaction with the addition of a phase transfer catalyst, such as, for example, TBACI (tetrabutylammonium chloride), TBABr (tetrabutylammonium bromide), TMACI (tetramethylammonium chloride) or TMABr (tetrabutylammonium bromide) or benzyl- triethylammonium chloride, benzyl-triethylammonium bromide or Aliquat, and/or by continuously distilling off the water formed during the reaction from the reaction mixture.
  • a phase transfer catalyst such as, for example, TBACI (tetrabutylammonium chloride), TBABr (tetra
  • An N,N'-diacylated hydrazine can be prepared by first reacting hydrazine hydrate with an acyl ester to form the monoacylated hydrazine and then, without intermediate isolation of the monoacylated hydrazine, adding an acyl anhydride to the highly concentrated aqueous- alcoholic reaction mixture.
  • the solvents can be removed completely from the reaction mixture, for example by concentration by evaporation, and the residue can be used further without being further purified.
  • alkyl radicals in the substituent definitions of the compounds of formula I contain from 1 to 5 carbon atoms and are, for example, methyl, ethyl, propyl, butyl or pentyl or branched isomers thereof.
  • Alkoxy radicals are derived from the mentioned alkyl radicals.
  • Alkenyl and alkynyl radicals each have from 2 to 5 carbon atoms and are, for example, ethenyl, propenyl, ethynyl and propynyl and branched isomers thereof, and also butenyl, butynyl, pentenyl, pentynyl and also branched and di-unsaturated isomers thereof.
  • the phenyl radicals may furthermore be mono- or poly-substituted by halogen, alkyl or alkoxy, for example each of which has from 1 to 4 carbon atoms, which preferably occupy the ortho or meta position or ortho and para positions.
  • Halogen is preferably fluorine, chlorine or bromine.
  • the reaction according to the invention is carried out in polar solvents, preferably in water or alcohols that preferably have a boiling point above 100 0 C, such as, for example, n-butanol, n-pentanol, cyclohexanol, phenol, benzyl alcohol and especially glycol, diethylene glycol, glycerol and such as methoxyisopropanol and ethoxyethanol, and also DMSO [(CH 3 ) 2 SO], sulfolane [(CH 2 ) 4 SO 2 ], NMP [(CH 2 J 3 CONCH 3 ], DMA [CH 3 CON(CH 3 ) 2 ] or DMF [HCON(CH 3 ) 2 ] or mixtures thereof, with preference being given to NMP, DMSO and, especially, water. It is also possible to use two-phase systems that contain, for example, water and an aromatic solvent, such as toluene, chlorobenzene, dichlorobenzene, xylene or anisole
  • the expression "elevated temperature” preferably denotes a temperature range of from 50 to 15O 0 C. Especially advantageously, a range of from 80 to 100 0 C is used.
  • the reaction can also be carried out under pressure, pressures of up to 10 bar preferably being used.
  • phase transfer catalyst such as, for example, TBACI (tetrabutylammonium chloride), TBABr (tetrabutylammonium bromide), TMACI (tetramethylammonium chloride) or TMABr (tetrabutylammonium bromide), or benzyl-triethylammonium chloride or benzyl- triethylammonium bromide or Aliquat
  • TBACI tetrabutylammonium chloride
  • TBABr tetrabutylammonium bromide
  • TMACI tetramethylammonium chloride
  • TMABr tetrabutylammonium bromide
  • benzyl-triethylammonium chloride or benzyl- triethylammonium bromide or Aliquat the reaction can be further improved in terms of yields.
  • Bases suitable for the reaction according to the invention are preferably hydroxides, carbonates and alcoholates of alkali metals and alkaline earth metals, with alkali metal hydroxides being preferred. Potassium hydroxide is especially suitable. Preferably, from 1 to 2 equivalents, especially from 1 to 1.3 equivalents, of base are used per acyl group to be removed.
  • the base can be used in solid form or can be used in solution in one of the mentioned polar solvents, for example in water in a concentration of from 10 to 70%, preferably from 40 to 65%.
  • the yields of isolated [1 ,4,5]-oxadiazepine are generally from 60 to 95%.
  • the purity of the [1 ,4,5]-oxadiazepine is usually about 90%.
  • the reaction mixture is extracted using an aromatic solvent that has poor miscibility with the reaction medium, such as chlorobenzene, at a temperature of from 20 to 100 0 C, preferably in the range from 60 to 80 0 C, thus yielding a solution comprising the [1 ,4,5]-oxadiazepine from which the latter can be isolated in customary manner, for example by distilling off the aromatic solvent.
  • the extraction can be carried out batchwise or continuously.
  • a salt that is inert towards the reaction mixture and soluble therein can be added thereto.
  • the salt used for that purpose is preferably the same salt as that obtained when the acyl group is removed, that is to say an acetate, for example potassium acetate.
  • an acetate for example potassium acetate.
  • direct separation of the [1 ,4,5]- oxadiazepine can in that way be achieved.
  • the process according to the invention can be carried out continuously or in batches (discontinuously, batchwise), with the batch procedure being preferred.
  • the reaction times are generally from 1 to 10 hours.
  • the batchwise reaction procedure is preferably carried out in a stirred vessel, and the continuous reaction procedure, for example, in a stirred vessel cascade.
  • the process according to the invention has the following advantages: higher volumetric yields can be achieved since, in the case of the reaction using hydrohalic acid, a viscous crystal suspension comprising the hydrohalide of the
  • [1 ,4,5]-oxadiazepine in question is formed which, at a certain concentration and above, seriously impairs the stirrability of the reaction mass by metering in the base and/or the 4,5-diacetyl-[1 ,4,5]-oxadiazepine, the reaction can be controlled in a simple manner the addition of the readily soluble salts enables extensive extraction of the [1 ,4,5]- oxadiazepine to be carried out reliability of the process is improved, because the thermal stability of the [1 ,4,5]- oxadiazepine derivatives is far better than that of the corresponding hydrohalides the isolation of [1 ,4,5]-oxadiazepines by extraction is considerably simpler than the isolation of the corresponding hydrohalides the cycle time is appreciably shorter
  • the [1 ,4,5]-oxadiazepine derivatives prepared according to the invention are used especially as intermediates in the preparation of herbicides of the tetrahydropyrazolodione type, which are described, for example, in WO 99/47525.
  • Batch 1 A mixture consisting of 47.2 g of water, 110 g of 98% potassium acetate and
  • 111.0 g of 4,5-diacetyl-[1 ,4,5]-oxadiazepine (content 92.1%) is prepared at from 90 to 95°C and, in the course of one hour, 118.2 g of aqueous 60% potassium hydroxide solution which has been heated to from 75 to 8O 0 C are added dropwise. The reaction mixture is then maintained at from 95 to 100 0 C for 4 hours. After cooling to from 70 to 75°C, extraction is carried out with chlorobenzene (first extraction: 1 x 225 g, second and third extraction each 112 g). Yield: 48.5 g of [1 ,4,5]-oxadiazepine in the extract, corresponding to 86.4% of theory.
  • Batch 2 Using half of the triple-extracted aqueous phase (containing 1.05 g of the title compound) from batch 1 as the initial charge, 1 14.O g of 4,5-diacetyl-[1 ,4,5]-oxadiazepine (content 89.5%) are introduced at from 90 to 95°C and, in the course of one hour, 118.2 g of aqueous 60% potassium hydroxide solution which has been heated to from 75 to 80 0 C are added dropwise. The reaction mixture is then maintained at from 95 to 100 0 C for 4 hours. After cooling to from 70 to 75°C, extraction is carried out.
  • a mixture of 35.2 g of water, 205 g of chlorobenzene, 100 g of potassium acetate and 96.6 g of 4,5-diacetyl-[1 ,4,5]-oxadiazepine (96.5% content) is heated to from 90 to 95°C. At that temperature, 107 g of aqueous 60% potassium hydroxide solution which has been heated to from 75 to 80 0 C are added dropwise in the course of 10 minutes. The reaction mixture is then maintained at from 90 to 100 0 C for 4 hours. After cooling to from 70 to 75°C, the phases are separated and the aqueous phase is then extracted twice using 100 g of chlorobenzene each time. Yield: 42.8 g of [1 ,4,5]-oxadiazepine in the extract, corresponding to 83.8% of theory.
  • a mixture consisting of 792 g of dimethyl sulfoxide, 140 g of N,N'-diacetylhydrazine (content 99.5%), 33 g of potassium carbonate, 142 g of potassium hydroxide (content 95%) and 6.6 g of tetramethylammonium chloride is prepared at from 80 to 85 0 C and evacuated to from 20 to 40 mbar. Under that vacuum and at the same temperature, 258 g of 2,2'-dichloro- diethyl ether are added dropwise in the course of 2 hours and the reaction mixture is then maintained under those conditions for 3 hours. During the dropwise addition and the maintenance period, the water formed under the reaction conditions is removed by distillation.
  • a mixture of 10.7 g of 4,5-dipropionyl-[1 ,4,5]-oxadiazepine (100%) and 2.0 g of water is prepared at from 95 to 100 0 C. 12.9 g of potassium hydroxide (50%) are metered in over the course of one hour and the mixture is then stirred for two hours.
  • Aqueous phase 32.5 g having a content of [1 ,4,5]-oxadiazepine of 2.82%, which corresponds to a yield of 18.0% of theory.
  • Chlorobenzene phase 13.0 g having a content of [1 ,4,5]-oxadiazepine of 10.45%, which corresponds to a yield of 26.6% of theory.
  • Example 9 Preparation of [1 ,4,5]-oxadiazepine A mixture of 15.53 g of 4,5-dibenzoyl-[1 ,4,5]-oxadiazepine (100%) and 168.0 g of water is prepared at from 95 to 100 0 C, 2.0 g of potassium hydroxide (95%) are metered in and then stirring is carried out for one hour. In order to complete the reaction, 0.27 g of tetramethyl- ammonium chloride is added, a further 18.34 g of potassium hydroxide (95%) is metered in over the course of several hours and then stirring is carried out at from 95 to 110 0 C for a further five hours. The reaction mixture is then cooled to room temperature, filtered and subsequently washed with 200.0 g of water.
  • Product filtrate 276.8 g having a content of [1 ,4,5]-oxadiazepine of 0.62%, which corresponds to a yield of 33.6% of theory.
  • a mixture of 11.6 g of 6,7,9, 10-tetrahydro-8-oxa-5a,10a-diazacyclohepta[b]naphthalene- 5,11-dione (100%) and 23.0 g of water is prepared at from 95 to 100 0 C and 6.78 g of potassium hydroxide (95%) are metered in over the course of several hours.
  • 0.27 g of tetramethylammonium chloride is added, a further 13.56 g of potassium hydroxide (95%) is metered in over the course of several hours and then stirring is carried out at from 95 to 1 10°C for a further five hours. In order that the reaction mixture remains stirrable, altogether a further 25 g of water is added.
  • chlorobenzene For working up, 28.0 g of chlorobenzene and 45 g of water are added at 95 0 C. The emulsion formed is cooled and is analysed without being separated. Chlorobenzene / water emulsion: 152.8 g having a content of [1 ,4,5]-oxadiazepine of 1.95%, which corresponds to a yield of 58.4% of theory.
  • Aqueous phase 420.0 g having a content of [1 ,4,5]-oxadiazepine of 5.38%, which corresponds to a yield of 22.1% of theory.
  • Chlorobenzene phase 484.0 g having a content of [1 ,4,5]-oxadiazepine of 10.91%, which corresponds to a yield of 51.7% of theory.
  • Aqueous phase 708.4 g having a content of [1 ,4,5]-oxadiazepine of 1.18%, which corresponds to a yield of 8.2% of theory.
  • Chlorobenzene phase 424.0 g having a content of [1 ,4,5]-oxadiazepine of 12.34%, which corresponds to a yield of 51.2% of theory.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A process for the preparation of [1,4,5]-oxidiazepine derivatives by reaction of 4,5-diacyl-[1,4,5]-oxidiazepines with a base.

Description

A PROCESS FOR THE PREPARATION " 1 , 4 , 5 ! -OXADIAZEPINE DERIVATIVES
The present invention relates to a novel process for the preparation of [1 ,4,5]- oxadiazepines and to their use as intermediates in the preparation of herbicides of the tetrahydropyrazolodione type.
According to WO 03/051853, [1 ,4,5]-oxadiazepines can be prepared by reacting various N,N'-diacylated hydrazines with, for example, 2,2'-dichlorodiethyl ether in a polar solvent to form 4,5-diacyl-[1 ,4,5]-oxadiazepines and then removing the two acyl groups using a hydrohalic acid.
Surprisingly, it has now been found that the preparation of [1 ,4,5]-oxadiazepine derivatives can be further improved by carrying out the conversion of 4,5-diacyl-[1 ,4,5]-oxadiazepines into the corresponding [1 ,4,5]-oxadiazepines using a base.
The present invention accordingly relates to a novel process for the preparation of [1 ,4,5]- oxadiazepine derivatives by reaction of a 4,5-diacyl-[1 ,4,5]-oxadiazepine with a base in a polar solvent and at elevated temperature.
Preferred 4,5-diacyl-[1 ,4,5]-oxadiazepines correspond to formula I
Figure imgf000002_0001
wherein R1 and R2 are each independently of the other hydrogen, CrC5alkyl, C1- C5haloalkyl, C2-C5alkenyl, C2-C5alkynyl, phenyl, alkylphenyl, halophenyl, alkoxyphenyl, benzyl, alkylbenzyl, halobenzyl, alkoxybenzyl, d-Csalkoxy-CrCsalkyl or C3-C6cycloalkyl, or R1 and R2 together are CrC4alkylene, 1 ,2-phenylene or 1 ,8-naphthylene, and R3 and R4 are each independently of the other hydrogen, d-Csalkyl, Ci -CSaIkOXy-C1 -C5alkyl, phenyl, alkylphenyl, halophenyl, alkoxyphenyl or benzyl.
Preferably, R1 and R2 are each independently of the other hydrogen or Ci-C5alkyl, especially methyl. R3 and R4 are preferably hydrogen. The 4,5-diacyl-[1 ,4,5]-oxadiazepines of formula I used according the invention as starting materials are known and can be prepared in a manner known per se, for example in the manner described in WO 03/051853. The yield of such starting materials can be improved in the case of the reaction of N,N'-diacylated hydrazines with, for example, 2,2'- dichlorodiethyl ether, by using hydroxides of alkali metals and alkaline earth metals as the base and by carrying out the reaction with the addition of a phase transfer catalyst, such as, for example, TBACI (tetrabutylammonium chloride), TBABr (tetrabutylammonium bromide), TMACI (tetramethylammonium chloride) or TMABr (tetrabutylammonium bromide) or benzyl- triethylammonium chloride, benzyl-triethylammonium bromide or Aliquat, and/or by continuously distilling off the water formed during the reaction from the reaction mixture.
An N,N'-diacylated hydrazine can be prepared by first reacting hydrazine hydrate with an acyl ester to form the monoacylated hydrazine and then, without intermediate isolation of the monoacylated hydrazine, adding an acyl anhydride to the highly concentrated aqueous- alcoholic reaction mixture. The solvents can be removed completely from the reaction mixture, for example by concentration by evaporation, and the residue can be used further without being further purified.
The alkyl radicals in the substituent definitions of the compounds of formula I contain from 1 to 5 carbon atoms and are, for example, methyl, ethyl, propyl, butyl or pentyl or branched isomers thereof. Alkoxy radicals are derived from the mentioned alkyl radicals. Alkenyl and alkynyl radicals each have from 2 to 5 carbon atoms and are, for example, ethenyl, propenyl, ethynyl and propynyl and branched isomers thereof, and also butenyl, butynyl, pentenyl, pentynyl and also branched and di-unsaturated isomers thereof. The phenyl radicals may furthermore be mono- or poly-substituted by halogen, alkyl or alkoxy, for example each of which has from 1 to 4 carbon atoms, which preferably occupy the ortho or meta position or ortho and para positions. Halogen is preferably fluorine, chlorine or bromine.
The reaction according to the invention is carried out in polar solvents, preferably in water or alcohols that preferably have a boiling point above 1000C, such as, for example, n-butanol, n-pentanol, cyclohexanol, phenol, benzyl alcohol and especially glycol, diethylene glycol, glycerol and
Figure imgf000003_0001
such as methoxyisopropanol and ethoxyethanol, and also DMSO [(CH3)2SO], sulfolane [(CH2)4SO2], NMP [(CH2J3CONCH3], DMA [CH3CON(CH3)2] or DMF [HCON(CH3)2] or mixtures thereof, with preference being given to NMP, DMSO and, especially, water. It is also possible to use two-phase systems that contain, for example, water and an aromatic solvent, such as toluene, chlorobenzene, dichlorobenzene, xylene or anisole.
The expression "elevated temperature" preferably denotes a temperature range of from 50 to 15O0C. Especially advantageously, a range of from 80 to 1000C is used.
The reaction can also be carried out under pressure, pressures of up to 10 bar preferably being used.
By adding a phase transfer catalyst, such as, for example, TBACI (tetrabutylammonium chloride), TBABr (tetrabutylammonium bromide), TMACI (tetramethylammonium chloride) or TMABr (tetrabutylammonium bromide), or benzyl-triethylammonium chloride or benzyl- triethylammonium bromide or Aliquat, the reaction can be further improved in terms of yields.
Bases suitable for the reaction according to the invention are preferably hydroxides, carbonates and alcoholates of alkali metals and alkaline earth metals, with alkali metal hydroxides being preferred. Potassium hydroxide is especially suitable. Preferably, from 1 to 2 equivalents, especially from 1 to 1.3 equivalents, of base are used per acyl group to be removed. The base can be used in solid form or can be used in solution in one of the mentioned polar solvents, for example in water in a concentration of from 10 to 70%, preferably from 40 to 65%.
The yields of isolated [1 ,4,5]-oxadiazepine are generally from 60 to 95%. The purity of the [1 ,4,5]-oxadiazepine is usually about 90%.
In the synthesis of [1 ,4,5]-oxadiazepine derivatives, the usual procedure is to introduce 4,5- diacyl-[1 ,4,5]-oxadiazepine into the polar solvent and heat the mixture. A stoichiometric amount or a suitable excess of base is then added and the reaction mixture is maintained at the selected temperature for approximately from 1 to 10 hours, preferably from 2 to 6 hours. The reaction mixture is extracted using an aromatic solvent that has poor miscibility with the reaction medium, such as chlorobenzene, at a temperature of from 20 to 1000C, preferably in the range from 60 to 800C, thus yielding a solution comprising the [1 ,4,5]-oxadiazepine from which the latter can be isolated in customary manner, for example by distilling off the aromatic solvent. The extraction can be carried out batchwise or continuously.
In principle, however, it is also possible to meter in the 4,5-diacyl-[1 ,4,5]-oxadiazepine instead of the base, or to meter in both components, base and 4,5-diacyl-[1 ,4,5]- oxadiazepine.
In order to facilitate isolation of the product, a salt that is inert towards the reaction mixture and soluble therein can be added thereto. The salt used for that purpose is preferably the same salt as that obtained when the acyl group is removed, that is to say an acetate, for example potassium acetate. At a suitable salt concentration, direct separation of the [1 ,4,5]- oxadiazepine can in that way be achieved.
The process according to the invention can be carried out continuously or in batches (discontinuously, batchwise), with the batch procedure being preferred. The reaction times are generally from 1 to 10 hours. The batchwise reaction procedure is preferably carried out in a stirred vessel, and the continuous reaction procedure, for example, in a stirred vessel cascade.
Compared with the known removal of the acyl groups using hydrohalic acid, the process according to the invention has the following advantages: higher volumetric yields can be achieved since, in the case of the reaction using hydrohalic acid, a viscous crystal suspension comprising the hydrohalide of the
[1 ,4,5]-oxadiazepine in question is formed which, at a certain concentration and above, seriously impairs the stirrability of the reaction mass by metering in the base and/or the 4,5-diacetyl-[1 ,4,5]-oxadiazepine, the reaction can be controlled in a simple manner the addition of the readily soluble salts enables extensive extraction of the [1 ,4,5]- oxadiazepine to be carried out reliability of the process is improved, because the thermal stability of the [1 ,4,5]- oxadiazepine derivatives is far better than that of the corresponding hydrohalides the isolation of [1 ,4,5]-oxadiazepines by extraction is considerably simpler than the isolation of the corresponding hydrohalides the cycle time is appreciably shorter
The [1 ,4,5]-oxadiazepine derivatives prepared according to the invention are used especially as intermediates in the preparation of herbicides of the tetrahydropyrazolodione type, which are described, for example, in WO 99/47525.
The following Examples further illustrate the invention.
Example 1 : Preparation of [1 ,4,5]-oxadiazepine
96.6 g of 4,5-diacetyl-[1 ,4,5]-oxadiazepine (content 96.5%) are introduced at from 75 to 800C into a solution of 67.2 g of water and 100 g of potassium acetate. Then, at the same temperature, 134.4 g of aqueous 50% potassium hydroxide solution are added dropwise in the course of 30 minutes. The reaction mixture is then maintained at from 90 to 1000C for 4 hours. After cooling to from 50 to 750C, extraction is carried out with chlorobenzene (1 x 200 g, 2 x 100 g). The combined chlorobenzene extracts contain 33.4 g of [1 ,4,5]- oxadiazepine, which corresponds to a yield of 65%.
Example 2: Preparation of [1 ,4,5]-oxadiazepine
96.6 g of 4,5-diacetyl-[1 ,4,5]-oxadiazepine (content 96.5%) are introduced in the course of 15 minutes, at from 80 to 850C, into a solution of 10.8 g of water, 100 g of potassium acetate and 123.2 g of aqueous 50% potassium hydroxide solution. The reaction mixture is then maintained at from 90 to 1000C for 4 hours. After cooling to from 50 to 75°C, extraction is carried out with chlorobenzene (1 x 200 g, 2 x 100 g). The combined chlorobenzene extracts contain 41.3 g of [1,4,5]-oxadiazepine, which corresponds to a yield of 80.9%.
Example 3: Preparation of [1 ,4,5]-oxadiazepine
Batch 1 : A mixture consisting of 47.2 g of water, 110 g of 98% potassium acetate and
111.0 g of 4,5-diacetyl-[1 ,4,5]-oxadiazepine (content 92.1%) is prepared at from 90 to 95°C and, in the course of one hour, 118.2 g of aqueous 60% potassium hydroxide solution which has been heated to from 75 to 8O0C are added dropwise. The reaction mixture is then maintained at from 95 to 1000C for 4 hours. After cooling to from 70 to 75°C, extraction is carried out with chlorobenzene (first extraction: 1 x 225 g, second and third extraction each 112 g). Yield: 48.5 g of [1 ,4,5]-oxadiazepine in the extract, corresponding to 86.4% of theory.
Batch 2: Using half of the triple-extracted aqueous phase (containing 1.05 g of the title compound) from batch 1 as the initial charge, 1 14.O g of 4,5-diacetyl-[1 ,4,5]-oxadiazepine (content 89.5%) are introduced at from 90 to 95°C and, in the course of one hour, 118.2 g of aqueous 60% potassium hydroxide solution which has been heated to from 75 to 800C are added dropwise. The reaction mixture is then maintained at from 95 to 1000C for 4 hours. After cooling to from 70 to 75°C, extraction is carried out. First extraction: combined second and third chlorobenzene extract from batch 1 (containing 9.3 g of the title compound); second and third extraction: each with 112 g of fresh chlorobenzene. Yield: 52.7 g of [1 ,4,5]-oxadiazepine in the extract, corresponding to 94.1% of theory.
Example 4: Preparation of [1 ,4,5]-oxadiazepine
A mixture of 35.2 g of water, 205 g of chlorobenzene, 100 g of potassium acetate and 96.6 g of 4,5-diacetyl-[1 ,4,5]-oxadiazepine (96.5% content) is heated to from 90 to 95°C. At that temperature, 107 g of aqueous 60% potassium hydroxide solution which has been heated to from 75 to 800C are added dropwise in the course of 10 minutes. The reaction mixture is then maintained at from 90 to 1000C for 4 hours. After cooling to from 70 to 75°C, the phases are separated and the aqueous phase is then extracted twice using 100 g of chlorobenzene each time. Yield: 42.8 g of [1 ,4,5]-oxadiazepine in the extract, corresponding to 83.8% of theory.
Example 5: Preparation of 4,5-diacetyl-[1 ,4,5]-oxadiazepine
A mixture consisting of 792 g of dimethyl sulfoxide, 140 g of N,N'-diacetylhydrazine (content 99.5%), 33 g of potassium carbonate, 142 g of potassium hydroxide (content 95%) and 6.6 g of tetramethylammonium chloride is prepared at from 80 to 850C and evacuated to from 20 to 40 mbar. Under that vacuum and at the same temperature, 258 g of 2,2'-dichloro- diethyl ether are added dropwise in the course of 2 hours and the reaction mixture is then maintained under those conditions for 3 hours. During the dropwise addition and the maintenance period, the water formed under the reaction conditions is removed by distillation. After cooling to from 20 to 250C, inorganic salt is filtered off, the filtrate is concentrated by evaporation and the residue is crystallised from 1-pentanol. 125.6 g of 4,5-diacetyl-[1 ,4,5]-oxadiazepine having a content of 93% are obtained, which corresponds to a yield of 52.3%. Example 6: Preparation of N.N'-diacetylhydrazine
In the course of 3 hours, at from 40 to 45°C, 191 g of acetic anhydride are metered into 279 g of a solution of 133.4 g of monoacetylhydrazine, 3.8% N.N'-diacetylhydrazine, 18% water, with the remainder being ethanol/ethyl acetate, and then the reaction mixture is maintained at the same temperature for 1 hour. All solvent is then distilled off with a gradual increase in temperature to from 165 to 1700C and a simultaneous reduction in pressure to from 10 to 20 mbar. The residue, 208 g, contains >98% N.N'-diacetylhydrazine, which corresponds to a yield of >98%.
Example 7: Preparation of [1 ,4,5]-oxadiazepine
A mixture of 18.6 g of 4,5-diacetyl-[1 ,4,5]-oxadiazepine (100%), 0.54 g of tetramethyl- ammonium chloride and 100 g of sulfolane is heated to Ti=120-125°C. In the course of 30 min., 4.0 g of potassium hydroxide (95%) are added and the reaction mixture is maintained at that temperature. 0.50 g of water is then added. After a further addition of 8.0 g of potassium hydroxide (95%) over a period of two hours, the reaction mixture is maintained at constant temperature for a further three hours. The reaction mixture is then cooled to room temperature and filtered, and the residue is subsequently washed with sulfolane. The sulfolane filtrate obtained (weight 214.9 g) has a content of 1.74%, which corresponds to a yield of 3.74 g/100% or 38.1% of theory.
Example 8: Preparation of [1 ,4,5]-oxadiazepine
A mixture of 10.7 g of 4,5-dipropionyl-[1 ,4,5]-oxadiazepine (100%) and 2.0 g of water is prepared at from 95 to 1000C. 12.9 g of potassium hydroxide (50%) are metered in over the course of one hour and the mixture is then stirred for two hours.
In order to complete the reaction, 0.27 g of tetramethylammonium chloride is added, a further 8.0 g of potassium hydroxide (95%) is metered in and then stirring is carried out at from 95 to 1100C for five hours. 7.0 g of chlorobenzene and 10.0 g of water are then added to the reaction mixture at 900C and the phases are separated at 7O0C.
Aqueous phase: 32.5 g having a content of [1 ,4,5]-oxadiazepine of 2.82%, which corresponds to a yield of 18.0% of theory.
Chlorobenzene phase: 13.0 g having a content of [1 ,4,5]-oxadiazepine of 10.45%, which corresponds to a yield of 26.6% of theory.
Example 9: Preparation of [1 ,4,5]-oxadiazepine A mixture of 15.53 g of 4,5-dibenzoyl-[1 ,4,5]-oxadiazepine (100%) and 168.0 g of water is prepared at from 95 to 1000C, 2.0 g of potassium hydroxide (95%) are metered in and then stirring is carried out for one hour. In order to complete the reaction, 0.27 g of tetramethyl- ammonium chloride is added, a further 18.34 g of potassium hydroxide (95%) is metered in over the course of several hours and then stirring is carried out at from 95 to 1100C for a further five hours. The reaction mixture is then cooled to room temperature, filtered and subsequently washed with 200.0 g of water.
Product filtrate: 276.8 g having a content of [1 ,4,5]-oxadiazepine of 0.62%, which corresponds to a yield of 33.6% of theory.
Example 10: Preparation of [1 ,4,5]-oxadiazepine
A mixture of 11.6 g of 6,7,9, 10-tetrahydro-8-oxa-5a,10a-diazacyclohepta[b]naphthalene- 5,11-dione (100%) and 23.0 g of water is prepared at from 95 to 1000C and 6.78 g of potassium hydroxide (95%) are metered in over the course of several hours. In order to complete the reaction, 0.27 g of tetramethylammonium chloride is added, a further 13.56 g of potassium hydroxide (95%) is metered in over the course of several hours and then stirring is carried out at from 95 to 1 10°C for a further five hours. In order that the reaction mixture remains stirrable, altogether a further 25 g of water is added. For working up, 28.0 g of chlorobenzene and 45 g of water are added at 950C. The emulsion formed is cooled and is analysed without being separated. Chlorobenzene / water emulsion: 152.8 g having a content of [1 ,4,5]-oxadiazepine of 1.95%, which corresponds to a yield of 58.4% of theory.
Example 11 : Preparation of [1 ,4,5]-oxadiazepine
A mixture of 210.9 g of pentanol-moistened 4,5-diacetyl-[1 ,4,5]-oxadiazepine (186.2 g -
100%) and 42.9 g of water is heated to Ti=100-105°C. Under vacuum, all the water and
1 -pentanol is distilled off. At the same temperature, 184.0 g of sodium hydroxide solution
(50%) are added in the course of 1 hour. During the sodium hydroxide addition, in parallel
36.8 g of water are added in order to keep the reaction mixture in solution. After a subsequent stirring time of one hour, the reaction mixture is cooled to Ti=90-95°C, 410 g of chlorobenzene are added and the phases are separated at Ti=90°C.
Aqueous phase: 420.0 g having a content of [1 ,4,5]-oxadiazepine of 5.38%, which corresponds to a yield of 22.1% of theory. Chlorobenzene phase: 484.0 g having a content of [1 ,4,5]-oxadiazepine of 10.91%, which corresponds to a yield of 51.7% of theory.
Example 12: Preparation of [1 ,4,5]-oxadiazepine
A mixture of 210.9 g of pentanol-moistened 4,5-diacetyl-[1 ,4,5]-oxadiazepine (186.2 g -
100%) and 42.9 g of water is heated to Ti=100-105°C. Under vacuum, all the water and
1 -pentanol is distilled off. At the same temperature, 550 g of lithium hydroxide solution
(10%) are added in the course of one hour.
After a subsequent stirring time of nine hours, the reaction mixture is cooled to Ti=90-95°C,
410 g of chlorobenzene are added and the phases are separated at Ti=90°C.
Aqueous phase: 708.4 g having a content of [1 ,4,5]-oxadiazepine of 1.18%, which corresponds to a yield of 8.2% of theory.
Chlorobenzene phase: 424.0 g having a content of [1 ,4,5]-oxadiazepine of 12.34%, which corresponds to a yield of 51.2% of theory.

Claims

What is claimed is:
1. A process for the preparation of a [1 ,4,5]-oxadiazepine derivative, which comprises reacting a 4,5-diacyl-[1 ,4,5]-oxadiazepine with a base in a polar solvent and at elevated temperature.
2. A process according to claim 1 , wherein the base used is an alkali metal hydroxide.
3. A process according to claim 1 , wherein the reaction is carried out in the presence of a salt that is soluble in the reaction mixture.
4. The use of the [1 ,4,5]-oxadiazepine prepared according to claim 1 in the preparation of a herbicide of the tetrahydropyrazolodione type.
PCT/EP2005/011432 2004-10-27 2005-10-25 A process for the preparation of [1,4,5]-oxadiazepine derivatives WO2006045587A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
KR1020077009539A KR101317353B1 (en) 2004-10-27 2005-10-25 A process for the preparation of [1,4,5]-oxadiazepane derivatives
BRPI0517390A BRPI0517390B8 (en) 2004-10-27 2005-10-25 process for the preparation of [1,4,5] -oxadiazepam derivatives
AT05795620T ATE430140T1 (en) 2004-10-27 2005-10-25 METHOD FOR PRODUCING AL1,4,5Ü-OXADIAZEPINE DERIVATIVES
EP05795620A EP1838683B1 (en) 2004-10-27 2005-10-25 A process for the preparation [1,4,5]-oxadiazepine derivatives
CA2579742A CA2579742C (en) 2004-10-27 2005-10-25 A process for the preparation of [1,4,5]-oxadiazepane derivatives
AU2005298824A AU2005298824C1 (en) 2004-10-27 2005-10-25 A process for the preparation of [1,4,5]-oxadiazepane derivatives
DE602005014280T DE602005014280D1 (en) 2004-10-27 2005-10-25 PROCESS FOR THE PREPARATION OF Ä1,4,5Ü-OXADIAZEPINE DERIVATIVES
CN2005800347444A CN101039926B (en) 2004-10-27 2005-10-25 Process for preparing a [1,4,5]-oxadiaz derivative
US11/577,805 US20090124800A1 (en) 2004-10-27 2005-10-25 process for the preparation of [1,4,5]-oxadiazepine derivatives
JP2007538323A JP5117858B2 (en) 2004-10-27 2005-10-25 Method for preparing 1,4,5-oxadiazepane derivative
EA200700766A EA011555B1 (en) 2004-10-27 2005-10-25 A process for the preparation of [1,4,5]-oxadiazepine derivatives
MX2007004591A MX2007004591A (en) 2004-10-27 2005-10-25 A process for the preparation of [1,4,5]-oxadiazepine derivatives.
DK05795620T DK1838683T3 (en) 2004-10-27 2005-10-25 Process for the preparation of [1,4,5] oxadiazepine derivatives
IL181766A IL181766A (en) 2004-10-27 2007-03-07 Process for the preparation of [1,4,5]-oxadiazepine derivatives and process for the preparation of a herbicide of the tetrahydropyrazolodione type
HK07113831.9A HK1108580A1 (en) 2004-10-27 2007-12-19 A process for the preparation of [1,4,5]-oxadiazepine derivatives
US13/100,601 US20110207925A1 (en) 2004-10-27 2011-05-04 Process for the preparation of [1,4,5]-oxadiazepine derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH1776/04 2004-10-27
CH17762004 2004-10-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/100,601 Division US20110207925A1 (en) 2004-10-27 2011-05-04 Process for the preparation of [1,4,5]-oxadiazepine derivatives

Publications (1)

Publication Number Publication Date
WO2006045587A1 true WO2006045587A1 (en) 2006-05-04

Family

ID=35708855

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/011432 WO2006045587A1 (en) 2004-10-27 2005-10-25 A process for the preparation of [1,4,5]-oxadiazepine derivatives

Country Status (21)

Country Link
US (2) US20090124800A1 (en)
EP (1) EP1838683B1 (en)
JP (1) JP5117858B2 (en)
KR (1) KR101317353B1 (en)
CN (2) CN101039926B (en)
AR (1) AR051341A1 (en)
AT (1) ATE430140T1 (en)
BR (1) BRPI0517390B8 (en)
CA (1) CA2579742C (en)
DE (1) DE602005014280D1 (en)
DK (1) DK1838683T3 (en)
EA (1) EA011555B1 (en)
ES (1) ES2325382T3 (en)
HK (1) HK1108580A1 (en)
IL (1) IL181766A (en)
MX (1) MX2007004591A (en)
PT (1) PT1838683E (en)
TW (1) TWI382021B (en)
UA (1) UA87710C2 (en)
WO (1) WO2006045587A1 (en)
ZA (1) ZA200701997B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012175666A1 (en) 2011-06-22 2012-12-27 Syngenta Participations Ag N-oxy pyrazolo-triazepine-dione derivatives
WO2018120093A1 (en) 2016-12-30 2018-07-05 泸州东方农化有限公司 Process for preparing oxadiazacyclo compound and use thereof
WO2019110613A1 (en) 2017-12-05 2019-06-13 Syngenta Participations Ag Chemical process for the synthesis of herbicidal pyrazolidinedione compounds
CN112522340A (en) * 2019-09-19 2021-03-19 四川利尔生物科技有限公司 Method for preparing 1-oxo-4, 5-diazepane by enzyme catalytic hydrolysis
WO2023208706A1 (en) * 2022-04-29 2023-11-02 Syngenta Crop Protection Ag Process for the preparation of [1,4,5]-oxadiazepine derivatives

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI316939B (en) * 2001-12-18 2009-11-11 Syngenta Participations Ag Process for the preparation of organic compounds
CN104974106B (en) * 2014-04-04 2019-02-22 浙江普洛康裕制药有限公司 5- alkyl-[1,3,4]-oxadiazoles -2- alkyl formate synthetic method
CN108264492B (en) * 2016-12-30 2020-04-14 浙江省诸暨合力化学对外贸易有限公司 Preparation process and application of oxadiazacyclo compound
CN108264493B (en) * 2016-12-30 2022-09-30 泸州东方农化有限公司 Process for preparing oxydiazacyclic compound and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017973A2 (en) * 1999-09-07 2001-03-15 Syngenta Participations Ag Novel herbicides
WO2001017351A1 (en) * 1999-09-07 2001-03-15 Syngenta Participations Ag Herbicidal composition
WO2003051853A1 (en) * 2001-12-18 2003-06-26 Syngenta Participations Ag PROCESS FOR THE PREPARATION OF `1,4,5!-OXADIAZEPINE DERIVATIVES

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2921068A (en) * 1957-11-19 1960-01-12 Sterling Drug Inc Mercurated 1, 6-diazabicyclo[4, 4, o] decane-7, 10-diones
JPH1029981A (en) * 1996-07-15 1998-02-03 Nippon Hidorajin Kogyo Kk Production of hexahydropyridazine compound
RU2221787C9 (en) * 1998-03-13 2020-11-26 Зингента Партисипейшнс Аг 3-hydroxy-4-aryl-5-oxopyrazoline derivatives having herbicidal action, a composition and a method of controlling weed

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017973A2 (en) * 1999-09-07 2001-03-15 Syngenta Participations Ag Novel herbicides
WO2001017351A1 (en) * 1999-09-07 2001-03-15 Syngenta Participations Ag Herbicidal composition
WO2003051853A1 (en) * 2001-12-18 2003-06-26 Syngenta Participations Ag PROCESS FOR THE PREPARATION OF `1,4,5!-OXADIAZEPINE DERIVATIVES

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CORRAL, C; LISSAVETZKY, J; QUINTANILLA, G: "New Method for the Synthesis of Chloro-Substituted Dibenzo[b,f][1,4,5]thiadiazepines and their 5,6-Dihydro Derivatives", JOURNAL OF ORGANIC CHEMISTRY., vol. 47, 1982, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC., pages 2214 - 2215, XP002367372 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012175666A1 (en) 2011-06-22 2012-12-27 Syngenta Participations Ag N-oxy pyrazolo-triazepine-dione derivatives
WO2018120093A1 (en) 2016-12-30 2018-07-05 泸州东方农化有限公司 Process for preparing oxadiazacyclo compound and use thereof
EP3564219A4 (en) * 2016-12-30 2019-12-04 Oriental (Luzhou) Agrochemicals. Co., Ltd. Process for preparing oxadiazacyclo compound and use thereof
WO2019110613A1 (en) 2017-12-05 2019-06-13 Syngenta Participations Ag Chemical process for the synthesis of herbicidal pyrazolidinedione compounds
CN112522340A (en) * 2019-09-19 2021-03-19 四川利尔生物科技有限公司 Method for preparing 1-oxo-4, 5-diazepane by enzyme catalytic hydrolysis
CN112522340B (en) * 2019-09-19 2023-05-09 四川利尔生物科技有限公司 Method for preparing 1-oxygen-4, 5-diazacycloheptane by enzyme catalysis hydrolysis
WO2023208706A1 (en) * 2022-04-29 2023-11-02 Syngenta Crop Protection Ag Process for the preparation of [1,4,5]-oxadiazepine derivatives

Also Published As

Publication number Publication date
EP1838683A1 (en) 2007-10-03
US20090124800A1 (en) 2009-05-14
BRPI0517390B1 (en) 2014-09-02
HK1108580A1 (en) 2008-05-09
MX2007004591A (en) 2007-06-25
CN101914072A (en) 2010-12-15
CA2579742A1 (en) 2006-05-04
CA2579742C (en) 2013-07-02
ES2325382T3 (en) 2009-09-02
CN101039926B (en) 2010-10-27
UA87710C2 (en) 2009-08-10
IL181766A (en) 2012-10-31
EA200700766A1 (en) 2007-10-26
ATE430140T1 (en) 2009-05-15
EA011555B1 (en) 2009-04-28
ZA200701997B (en) 2008-07-30
BRPI0517390B8 (en) 2016-04-26
DK1838683T3 (en) 2009-08-10
BRPI0517390A (en) 2008-10-07
TW200619213A (en) 2006-06-16
KR101317353B1 (en) 2013-10-14
DE602005014280D1 (en) 2009-06-10
AU2005298824A1 (en) 2006-05-04
TWI382021B (en) 2013-01-11
KR20070068426A (en) 2007-06-29
US20110207925A1 (en) 2011-08-25
PT1838683E (en) 2009-07-22
JP5117858B2 (en) 2013-01-16
EP1838683B1 (en) 2009-04-29
CN101039926A (en) 2007-09-19
IL181766A0 (en) 2007-07-04
JP2008517965A (en) 2008-05-29
AU2005298824B2 (en) 2012-04-12
AR051341A1 (en) 2007-01-03

Similar Documents

Publication Publication Date Title
US20110207925A1 (en) Process for the preparation of [1,4,5]-oxadiazepine derivatives
WO2017189339A1 (en) Process for the preparation of n-[(5-pyrimidinyl)methyl]-2-pyridinamines
EP1458696B1 (en) Process for the preparation of (1,4,5)-oxadiazepine derivatives
AU2005298824C1 (en) A process for the preparation of [1,4,5]-oxadiazepane derivatives
FI101222B (en) A process for the preparation of therapeutically active quinolin-2-ylmethoxyphenyl derivatives
HU225020B1 (en) Process for the preparation of 1-aryl-3-cyclopropyl-1,3-propanediones
US5442075A (en) Process for the production of 2-substituted 5-chlorimidazole-4-carbaldehydes
JP4361290B2 (en) Esculetin derivative, method for producing the same, and method for purifying esculetin
KR20020035171A (en) Process to prepare aryltriazolinones and novel intermediates thereto
JPS63297362A (en) Alkoxy substituted maleic acid imide and maleic acid anhydride, manufacture and use
EP0639558B1 (en) Process for preparation of 1-acyl-2-substituted-hydrazines
EP2003112A1 (en) Method for producing carboxylic acid compound
UA82734C2 (en) 5-alkyl-2-phenyl-4,5-dihydro-2h-pyrazolo[4,3-c]-quinazolines and process for the preparation thereof
WO2009002955A1 (en) Process for the preparation of (2r)-2-[4-(7-bromo-2-quinolyloxy)phenoxy]propanoic acid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV LY MD MG MK MN MW MX MZ NA NG NO NZ OM PG PH PL PT RO RU SC SD SG SK SL SM SY TJ TM TN TR TT TZ UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IS IT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007/01997

Country of ref document: ZA

Ref document number: 181766

Country of ref document: IL

Ref document number: 2579742

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2070/DELNP/2007

Country of ref document: IN

Ref document number: 2005298824

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005795620

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200580034744.4

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/004591

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1200700840

Country of ref document: VN

ENP Entry into the national phase

Ref document number: 2005298824

Country of ref document: AU

Date of ref document: 20051025

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005298824

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 11577805

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2007538323

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020077009539

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 200700766

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2005795620

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0517390

Country of ref document: BR